{"id":180691,"date":"2026-02-13T10:18:42","date_gmt":"2026-02-13T15:18:42","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180691"},"modified":"2026-02-13T10:18:42","modified_gmt":"2026-02-13T15:18:42","slug":"torrent-pharma-integrates-jb-pharma-amid-strong-quarterly-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/torrent-pharma-integrates-jb-pharma-amid-strong-quarterly-results\/","title":{"rendered":"Torrent Pharma Integrates JB Pharma Amid Strong Quarterly Results"},"content":{"rendered":"\n

Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM)<\/strong>, a leading Indian pharmaceutical company with a market capitalization of approximately \u20b987,000 crore, reported consolidated revenue of \u20b93,303 crore for the third quarter ended December 31, 2025, up 18% year-on-year (YoY). Net profit rose 26% to \u20b9635 crore, compared with \u20b9503 crore in the year-ago period.<\/p>\n\n\n\n

The results reflected steady growth across domestic and international markets, along with exceptional items related to the acquisition of JB Chemicals & Pharmaceuticals Ltd (JB Pharma) and regulatory adjustments.<\/p>\n\n\n\n

Operational Performance and Margins<\/strong><\/h2>\n\n\n\n

Torrent\u2019s operating EBITDA for Q3 FY26 reached \u20b91,088 crore, with an operating margin of 33%, while gross margin remained stable at 76%. The company declared an interim dividend of \u20b929 per share of \u20b95 (580%), payable in early March 2026.<\/p>\n\n\n\n

Standalone net profit and revenue trends were consistent with consolidated figures. Margins benefited from operational efficiencies, partially offsetting higher costs associated with integration of recent acquisitions and regulatory compliance.<\/p>\n\n\n\n

Strategic Acquisition of JB Chemicals & Pharma<\/strong><\/h2>\n\n\n\n

The quarter saw progress in Torrent\u2019s acquisition of a controlling stake in JB Pharma, which now stands at approximately 48.8%, including shares purchased through an open offer and employee agreements. The company initiated a merger scheme, under which 51 Torrent shares will be issued for every 100 JB Pharma shares.<\/p>\n\n\n\n

Exceptional items of \u20b910 crore were recorded in connection with regulatory and statutory fees associated with the acquisition. Following the merger, Torrent is expected to rank 5th in the Indian Pharmaceutical Market (IPM), enhancing its presence in chronic and specialty therapy segments.<\/p>\n\n\n\n

Geographic Revenue Contribution<\/strong><\/h2>\n\n\n\n

Revenue growth was geographically broad-based:<\/p>\n\n\n\n

    \n
  • India:<\/strong> \u20b91,798 crore, up 14% YoY, outperforming IPM growth of approximately 10% in chronic and sub-chronic segments such as Cardiovascular and Diabetes.<\/li>\n\n\n\n
  • Brazil:<\/strong> \u20b9371 crore, up 27% YoY (10% in constant currency), maintaining Torrent\u2019s position as the leading Indian pharma company in the market.<\/li>\n\n\n\n
  • United States:<\/strong> \u20b9321 crore, up 19% YoY, with constant currency growth of 16% over the nine-month period, supported by recent product launches.<\/li>\n\n\n\n
  • Germany:<\/strong> \u20b9304 crore, up 8%, though constant currency revenue declined 6% due to third-party supply disruptions.<\/li>\n<\/ul>\n\n\n\n

    Torrent\u2019s global operations now cover over 50 countries, with specialty-focused products accounting for 76% of India revenues.<\/p>\n\n\n\n

    Product Portfolio and R&D Investments<\/strong><\/h2>\n\n\n\n

    Torrent maintains a diversified portfolio across chronic and sub-chronic therapies, including Cardiovascular, Gastrointestinal, Central Nervous System, Pain Management, and Cosmo-Dermatology.<\/p>\n\n\n\n

    Research and development expenditure for the quarter was \u20b9154 crore, representing approximately 5% of revenue. The company operates eight manufacturing facilities, five of which are USFDA-approved, and employs over 750 scientists. In Brazil, 60 products are under ANVISA review, signaling potential future launches.<\/p>\n\n\n\n

    Financial Position and Credit Metrics<\/strong><\/h2>\n\n\n\n

    Torrent maintains a conservative financial structure, with standalone debt-equity ratio of 0.14 and consolidated ratio of 0.21. Interest coverage ratios stand at 23.06x (standalone) and 18.86x (consolidated). During the quarter, the company repaid \u20b9143 crore of listed secured non-convertible debentures.<\/p>\n\n\n\n

    Regulatory Developments and Government Schemes<\/strong><\/h2>\n\n\n\n

    The company addressed recent regulatory and tax changes:<\/p>\n\n\n\n

      \n
    • Labor Codes:<\/strong> India\u2019s consolidation of 29 labor laws into four codes, effective November 21, 2025, was assessed as not material for Torrent.<\/li>\n\n\n\n
    • Taxation:<\/strong> Transition to the 115BAA tax regime resulted in a net reversal of deferred tax liabilities of \u20b9151 crore.<\/li>\n\n\n\n
    • NPPA Settlement:<\/strong> Torrent resolved a long-standing pricing dispute with the National Pharmaceutical Pricing Authority, closing the litigation.<\/li>\n<\/ul>\n\n\n\n

      These adjustments were reflected in Q3 FY26 results, alongside acquisition-related exceptional items.<\/p>\n\n\n\n

      Competitive Positioning and Sector Outlook<\/strong><\/h2>\n\n\n\n

      Torrent competes with peers such as Sun Pharma<\/strong> and Lupin<\/strong>, leveraging its specialty therapy portfolio and regulated market presence. In international markets, Torrent holds leading positions among Indian pharma companies in Brazil and Germany, while maintaining global operations in 50+ countries.<\/p>\n\n\n\n

      The Indian pharmaceutical sector faces continued pricing pressures, rising input costs, and regulatory scrutiny, particularly in export markets. Torrent\u2019s geographic diversification and chronic therapy focus provide resilience against these macro pressures.<\/p>\n\n\n\n

      Guidance and Analyst Commentary<\/strong><\/h2>\n\n\n\n

      The company did not provide updated FY26 guidance. No analyst upgrades, downgrades, or price-target revisions were reported with the Q3 release.<\/p>\n\n\n\n

      Summary<\/strong> <\/h2>\n\n\n\n

      Torrent Pharmaceuticals delivered robust Q3 FY26 results, supported by double-digit revenue growth, stable margins, and strategic acquisition activity. Its R&D investments, geographic expansion, and specialty therapy focus position the company to sustain growth in domestic and international pharmaceutical markets.<\/p>\n","protected":false},"excerpt":{"rendered":"

      Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM), a leading Indian pharmaceutical company with a market capitalization of approximately \u20b987,000 crore, reported consolidated revenue of \u20b93,303 crore for the third quarter ended December 31, 2025, up 18% year-on-year (YoY). Net profit rose 26% to \u20b9635 crore, compared with \u20b9503 crore in the year-ago period. The results reflected steady […]<\/p>\n","protected":false},"author":2393,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,6352],"tags":[3059,16481,16482],"class_list":["post-180691","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-research-summary","tag-biopharma","tag-torntpharm","tag-torrent-pharmaceuticals-ltd"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172440,"url":"https:\/\/alphastreet.com\/india\/torrent-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":180691,"position":0},"title":"Torrent Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 17, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b93,302 crore, up 14% YoY from \u20b92,889 crore EBITDA: \u20b91,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Torrent Pharmaceuticals Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166613,"url":"https:\/\/alphastreet.com\/india\/torntpharm-q3-2024-2025-call-highlights-margins-surge-india-growth-insulin-recovery\/","url_meta":{"origin":180691,"position":1},"title":"TORNTPHARM Q3 2024-2025 Call Highlights: Margins Surge, India Growth, & Insulin Recovery!","author":"Praveen","date":"January 29, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd., a leading pharma company in India, in its Q3 earnings call addressed that it expects to maintain a 32.5% margin in Q4, with annual improvements of 50-100 basis points, while its insulin CMO business anticipates significant spillover beyond the normal quarterly run rate. In India, the company\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":131845,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":180691,"position":2},"title":"Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY23 Earnings Concall Management Update: TORNTPHARM launched four products in 1Q23 and will be launching 4 products in 2Q23, of which three are expected to be day-one launches. Q&A Highlights: Tushar Manudhane of Motilal Oswal asked about shortage of medicine in Germany\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139387,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":180691,"position":3},"title":"Torrent Pharmaceuticals Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 27, 2023","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about 5-6 products in FY23. Q&A Highlights: [00:06:50] Saion Mukherjee of Nomura Securities asked about the organic growth without Curatio. Sudhir Menon CFO replied that the base business growth\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147571,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q4fy23-revenue-grows-by-17\/","url_meta":{"origin":180691,"position":4},"title":"Torrent Pharmaceuticals Ltd Q4FY23 revenue grows by 17%","author":"Chirag Gupta","date":"May 30, 2023","format":false,"excerpt":"Torrent Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of \u20b92,452 Crore, up from \u20b9 Crore year on year depicting a growth of 17%. Consolidated Net Profit of \u20b9287 Crore, up 343% from -(\u20b9118) Crore in the same quarter of the previous year. The Earnings per Share is \u20b98.48, up\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/aaf214f9-9299-4354-adcf-b4303477732d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":155267,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":180691,"position":5},"title":"Torrent Pharmaceuticals Ltd Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"October 24, 2023","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2 FY24 Earnings Concall Revenue Growth Across Key Markets India business revenue grew 18% year-on-year; 12% growth excluding Curatio acquisition. Strong constant currency revenue growth of 8% in Germany and 23% in Brazil. US revenues declined due to loss of low-margin business and\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2393"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180691"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180691\/revisions"}],"predecessor-version":[{"id":180692,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180691\/revisions\/180692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}